Robot SurgeryNCT06973083
Efficacy and Safety of Robot-assisted Endoscopic Submucosal Dissection for Colorectal Neoplasm
A study testing FASTER-assisted ESD and Conventional ESD in people with Robot Surgery and Endoscopic Submucosal Dissection (ESD), run by Shandong University at 1 site in China.
Trial summary
The objective of this study is to investigate the role of the flexible auxiliary single-arm transluminal endoscopic robot (FASTER) system in colorectal endoscopic submucosal dissection (ESD) and to validate its superiority over conventional ESD in terms of reducing procedural difficulty, shortening procedure time, and… Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Robot Surgery, Endoscopic Submucosal Dissection (ESD), Colorectal Neoplasms
- What is being tested?
- FASTER-assisted ESD and Conventional ESD
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 104 participants
- Where
- 1 siteChina
- Study dates
- 1 Jun 2025to 30 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients aged 18-85.
- Patients with pathologically verified colorectal neoplasms scheduled to undergo ESD.
Who cannot join
- Patients have lesions with confirmed or potential deep submucosal invasion or lymph node metastasis or other conditions that are not suitable for endoscopic therapy.
- Patients with severe underlying diseases precluding endotracheal intubation, general anesthesia, or surgery.
- Patients have a history of colorectal malignancy with previous radiotherapy or operative treatment leading to changes in colorectal structure.
- Patients have lesions with local recurrence after endoscopic resection.
- Patients unable to obtain informed consent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Qilu Hospital of Shandong University
Jinan, Shandong, 250012
Xiuli Zuo, Professor, MD, PhD, +86 18560080066, zuoxiuli@sdu.edu.cn
About this study
Official title: Efficacy and Safety of Robot-assisted Endoscopic Submucosal Dissection for Colorectal Neoplasm: A Randomized Controlled Trial.
The objective of this study is to investigate the role of the flexible auxiliary single-arm transluminal endoscopic robot (FASTER) system in colorectal endoscopic submucosal dissection (ESD) and to validate its superiority over conventional ESD in terms of reducing procedural difficulty, shortening procedure time, and enhancing procedural safety.
The main questions it aims to answer are:
Read more
Does the use of the FASTER system improve the dissection speed of the ESD procedure? Does the use of the FASTER system reduce the procedure and dissection time, improving the efficacy of the ESD procedure? Does the use of the FASTER system reduce the rate of perforation and hemorrhage, improving the safety of the ESD procedure? Researchers will compare FASTER-assisted ESD and conventional ESD to evaluate the safety and efficacy of the FASTER system.
Participants will:
Be randomly assigned to the group with ESD using the traditional procedure or to the group with ESD assisted by the FASTER system.
Keep a diary of their symptoms after the procedure. ESD has gained widespread acceptance as the standard method for treating early-stage gastrointestinal cancers. However, ESD is a technically demanding and intricate procedure that requires advanced proficiency of operators, with a heightened risk of complications such as hemorrhage and perforation. The inherent challenges of the colorectal ESD are further amplified by the thin mucosa, highly tortuous and flexible lumen, and occasional obstruction of lesions by mucosal folds, all of which collectively elevate both the procedural difficulty and the probability of postoperative complications. Adequate exposure of the submucosa layer through effective tissue traction is vital for the safe and effective performance of ESD. The FASTER system is designed to overcome this technical difficulty.
- Being tested
- FASTER-assisted ESD, Conventional ESD
- Medical subject headings
- Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FASTER-assisted ESDProcedure or surgery
The patients who are randomly assigned to the FASTER-assisted ESD group will undergo the ESD procedure with the assistance of the FASTER system.
Conventional ESDProcedure or surgery
The patients who are randomly assigned to the conventional ESD group will undergo the ESD following the clinically established pattern.
| Study group | Role | What they receive |
|---|---|---|
| FASTER-assisted ESD | Experimental | Patients in this group undergo ESD with the assistance of the FASTER system. Receives: Procedure: FASTER-assisted ESD |
| Conventional ESD | Active comparator | Patients in this group undergo ESD following the clinically established pattern. Receives: Procedure: Conventional ESD |
What is being measured
The primary outcome is the main question the study is designed to answer.
procedure time
Procedure time is the time from the beginning of injection to the completion of dissection.
Measured: Within 24 hours after the procedure.
Secondary outcomes (18)
dissection time
Dissection time is the time from the beginning of dissection to the completion of dissection.
Measured: Within 24 hours after the procedure.
dissection speed
Dissection speed is defined as the lesion area divided by the dissection time.
Measured: Within 24 hours after the procedure.
en bloc resection rate
En bloc dissection refers to the complete removal of the entire lesion in a single piece.
Measured: Within 24 hours after the procedure.
R0 resection rate
R0 resection is defined as en bloc resection with negative vertical and horizontal margins.
Measured: Within 24 hours after the procedure.
perforation rate
Perforation were defined as: endoscopic visualization of mural transection during ESD, or postoperative clinical signs combined with radiologically confirmed pneumoperitoneum.
Measured: Within 24 hours after the procedure.
postoperative hemorrhage rate
Post-ESD hemorrhage was strictly defined as meeting ≥1 of: hematemesis or melena with dizziness, hemoglobin decline >20 g/L, SBP drop >20 mmHg or HR elevation >20 bpm, presence of bloody fluid in nasogastric tube drainage, or active bleeding confirmed by repeat endoscopy.
Measured: Within 24 hours after the procedure.
intraoperative hemorrhage rate
Measured: Within 24 hours after the procedure.
the proportion of intraoperative hemorrhage ≥ grade 2
Intraoperative hemorrhage is divided into four grades: Grade 0 means no significant bleeding is observed during the procedure. Grade 1 means minimal bleeding, which could stop spontaneously or be easily controlled by cauterization with a dual knife. Grade 2 refers to minor hemorrhage that requires multiple cauterizations with a dual knife or hemostatic forceps. Grade 3 indicates massive hemorrhage that requires multiple cauterizations with hemostatic forceps.
Measured: Within 24 hours after the procedure.
hemostasis time
Hemostasis time referred to the time from the detection of submucosal bleeding until hemostasis was completed.
Measured: Within 24 hours after the procedure.
muscular injury rate
Muscular injury is described as visible damage to the muscularis propria.
Measured: Within 24 hours after the procedure.
direct-vision dissection rate
Direct-vision dissection time is the time that the endoscopist can directly observe the tip of the dual knife and the submucosal layer at the same time. By dividing the direct-vision dissection time by the total dissection duration, the direct-vision dissection rate is calculated.
Measured: Within 24 hours after the procedure.
postoperative pain score
Postoperative pain score was assessed via the 11-point Numerical Rating Scale (NRS: 0=no pain, 10=worst imaginable pain). Patients independently rated their pain intensity on postoperative day 3, with scores categorized as mild (1-3), moderate (4-6), or severe (7-10).*
Measured: 3 days after the procedure.
the frequency of supplemental injections
Supplemental injection refers to injections performed after the beginning of the dissection.
Measured: Within 24 hours after the procedure.
the supplemental injections time
The time of supplementary injection is from the insertion of the injection needle into the submucosal layer until the injection is completed and the needle is withdrawn.
Measured: Within 24 hours after the procedure.
Volume of injection fluid used in supplemental injections
Measured: Within 24 hours after the procedure.
the frequency of intraoperative patient positioning changes
Measured: Within 24 hours after the procedure.
time required for patient positioning changes
Measured: Within 24 hours after the procedure.
NASA-TLX scale scores
Measured: Within 24 hours after the procedure.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 May 2025
- Study start1 Jun 2025 (estimated)
- Primary completion30 Dec 2026 (estimated)
- Study completion30 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Robot SurgeryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 104 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shandong University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Xiuli Zuo, Shandong University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06973083
- Sponsor's protocol ID
- QLCR20230523
- Status last verified
- May 2025
- First submitted
- 7 May 2025
- Last updated
- 21 May 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of Robot-assisted Endoscopic Submucosal Dissection for Colorectal Neoplasm: A Randomized Controlled Trial.
- ClinicalTrials.gov ID
- NCT06973083
- Acronym / sponsor ID
- QLCR20230523
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 104 participants (estimated)
- Lead sponsor
- Shandong UniversityUniversity, hospital or other
- Study start
- 1 Jun 2025 (estimated)
- Primary completion
- 30 Dec 2026 (estimated)
- Study completion
- 30 Dec 2026 (estimated)
- First posted
- 15 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to investigate the role of the flexible auxiliary single-arm transluminal endoscopic robot (FASTER) system in colorectal endoscopic submucosal dissection (ESD) and to validate its superiority over conventional ESD in terms of reducing procedural difficulty, shortening procedure time, and enhancing procedural safety.
The main questions it aims to answer are:
Does the use of the FASTER system improve the dissection speed of the ESD procedure? Does the use of the FASTER system reduce the procedure and dissection time, improving the efficacy of the ESD procedure? Does the use of the FASTER system reduce the rate of perforation and hemorrhage, improving the safety of the ESD procedure? Researchers will compare FASTER-assisted ESD and conventional ESD to evaluate the safety and efficacy of the FASTER system.
Participants will:
Be randomly assigned to the group with ESD using the traditional procedure or to the group with ESD assisted by the FASTER system.
Keep a diary of their symptoms after the procedure. ESD has gained widespread acceptance as the standard method for treating early-stage gastrointestinal cancers. However, ESD is a technically demanding and intricate procedure that requires advanced proficiency of operators, with a heightened risk of complications such as hemorrhage and perforation. The inherent challenges of the colorectal ESD are further amplified by the thin mucosa, highly tortuous and flexible lumen, and occasional obstruction of lesions by mucosal folds, all of which collectively elevate both the procedural difficulty and the probability of postoperative complications. Adequate exposure of the submucosa layer through effective tissue traction is vital for the safe and effective performance of ESD. The FASTER system is designed to overcome this technical difficulty.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| FASTER-assisted ESD | Experimental | Procedure: FASTER-assisted ESDPatients in this group undergo ESD with the assistance of the FASTER system. |
| Conventional ESD | Active comparator | Procedure: Conventional ESDPatients in this group undergo ESD following the clinically established pattern. |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Patients aged 18-85.
- Patients with pathologically verified colorectal neoplasms scheduled to undergo ESD.
Key exclusion criteria (5 listed)
- Patients have lesions with confirmed or potential deep submucosal invasion or lymph node metastasis or other conditions that are not suitable for endoscopic therapy.
- Patients with severe underlying diseases precluding endotracheal intubation, general anesthesia, or surgery.
- Patients have a history of colorectal malignancy with previous radiotherapy or operative treatment leading to changes in colorectal structure.
- Patients have lesions with local recurrence after endoscopic resection.
- Patients unable to obtain informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FASTER-assisted ESDThe patients who are randomly assigned to the FASTER-assisted ESD group will undergo the ESD procedure with the assistance of the FASTER system. | Procedure or surgery | FASTER-assisted ESD |
| Conventional ESDThe patients who are randomly assigned to the conventional ESD group will undergo the ESD following the clinically established pattern. | Procedure or surgery | Conventional ESD |
Primary outcome
procedure time
Time frame: Within 24 hours after the procedure.
Procedure time is the time from the beginning of injection to the completion of dissection.
18 secondary outcomes
dissection time
Time frame: Within 24 hours after the procedure.
dissection speed
Time frame: Within 24 hours after the procedure.
en bloc resection rate
Time frame: Within 24 hours after the procedure.
R0 resection rate
Time frame: Within 24 hours after the procedure.
perforation rate
Time frame: Within 24 hours after the procedure.
postoperative hemorrhage rate
Time frame: Within 24 hours after the procedure.
intraoperative hemorrhage rate
Time frame: Within 24 hours after the procedure.
the proportion of intraoperative hemorrhage ≥ grade 2
Time frame: Within 24 hours after the procedure.
hemostasis time
Time frame: Within 24 hours after the procedure.
muscular injury rate
Time frame: Within 24 hours after the procedure.
direct-vision dissection rate
Time frame: Within 24 hours after the procedure.
postoperative pain score
Time frame: 3 days after the procedure.
the frequency of supplemental injections
Time frame: Within 24 hours after the procedure.
the supplemental injections time
Time frame: Within 24 hours after the procedure.
Volume of injection fluid used in supplemental injections
Time frame: Within 24 hours after the procedure.
the frequency of intraoperative patient positioning changes
Time frame: Within 24 hours after the procedure.
time required for patient positioning changes
Time frame: Within 24 hours after the procedure.
NASA-TLX scale scores
Time frame: Within 24 hours after the procedure.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 May 2025.
Related trials for Robot Surgery
RecruitingPhase 2
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
Head and Neck Cancer, Head and Neck Squamous Cell Cancer
RecruitingObservational study
GENERATE - Next GENERATion of GynEcological Surgery - Robotic Assisted Surgery in Gynecological Indications
GYN Disorders
Not yet recruitingObservational study
A Study Comparing Single-Port and Multi-Port Robot-Assisted Surgery in Patients With Prostate or Kidney (Renal) Cancer
Prostate Cancer, Renal Cancer
Active, not recruiting
Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)
Bladder Cancer, Prostate Cancer
Not yet recruitingObservational study
Fluid Responsiveness in Laparoscopic Surgery: End-Expiratory Occlusion Test Versus Mini-Fluid Challenge
Fluid Responsiveness, Laparoscopic Surgery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing FASTER-assisted ESD and Conventional ESD in people with Robot Surgery and Endoscopic Submucosal Dissection (ESD), run by Shandong University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 21 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xiuli Zuo, Professor, MD, PhD (86+18560080066, zuoxiuli@sdu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
procedure time (time frame: Within 24 hours after the procedure.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 May 2025.